Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
⚠️ Updated analysis. The primary endpoint (investigator-assessed PFS) was previously reported. This analysis reports overall survival at 34.6 months median follow-up.
🎯 Clinical Bottom Line
MONALEESA-7 demonstrated that adding ribociclib to endocrine therapy plus ovarian suppression significantly prolonged overall survival in premenopausal/perimenopausal women with HR+/HER2− advanced breast cancer — the first CDK4/6 inhibitor to show a significant OS benefit in any breast cancer population at time of publication. This is the standard first-line approach for premenopausal patients.
Key Result: 42-month OS — 70.2% vs 46.0%, HR 0.71 (95% CI 0.54–0.95; P=0.00973)
Safety Signal: Grade 3 or 4 neutropenia in 63.5% of ribociclib patients — manageable with dose modifications but requires routine CBC monitoring.
✅ Patient Eligibility
Must Have:
- HR+/HER2− advanced breast cancer (locoregionally recurrent or metastatic)
- Premenopausal or perimenopausal
- First-line endocrine therapy setting (no prior endocrine therapy for advanced disease)
- ECOG 0–1
- Measurable disease or predominantly lytic bone lesion
Cannot Have:
- Previous CDK4/6 inhibitor treatment
- More than one prior line of chemotherapy for advanced disease
- Disease amenable to curative therapy
💊 Dosing Quick Guide
Experimental Regimen
Ribociclib: 600 mg orally once daily, days 1–21 of 28-day cycle Goserelin: 3.6 mg subcutaneously, day 1 of each 28-day cycle Endocrine partner: Letrozole 2.5 mg OR anastrozole 1 mg OR tamoxifen 20 mg orally once daily continuously Duration: Until disease progression (median treatment ~2 years)
Control Regimen
Placebo plus identical goserelin and endocrine partner dosing (median treatment ~1 year)
Key Dose Modifications [2]
Per FDA prescribing information — not trial protocol - Dose reductions: 600 mg → 400 mg → 200 mg; discontinue if 200 mg not tolerated - Hold for grade ≥3 neutropenia (ANC <1000/mm³); resume at next lower dose when ≥1000/mm³ - ECG monitoring required: baseline, ~day 14 of cycle 1, beginning of cycle 2, and as clinically indicated
Mechanism: Ribociclib is a selective CDK4/6 inhibitor that blocks retinoblastoma protein phosphorylation, preventing G1-to-S cell-cycle progression in ER+ breast cancer cells [2].
⚠️ Safety Snapshot
| Grade 3 or 4 Toxicities | Ribociclib | Placebo |
|---|---|---|
| Neutropenia | 63.5% | 4.5% |
| Hepatobiliary toxic effects | 11% | 6.8% |
| QT prolongation | 1.8% | 1.2% |
⚠️ Neutropenia: Grade 3 or 4 in 63.5% — routine CBC monitoring required; dose modification per prescribing information.
⚠️ QT prolongation: Grade 3 or 4 in 1.8% — no symptomatic arrhythmias or torsades de pointes observed. ECG monitoring required.
Key safety metrics:
- Treatment-related deaths: Not reported in this publication
- Discontinuations due to AE: Not reported in this publication
- Dose reductions: Not reported in this publication
No new safety signals observed after ~2 years median treatment exposure.
📊 Key Numbers
Median follow-up: 34.6 months
| Outcome | Ribociclib (n=335) | Placebo (n=337) | HR (95% CI) | p-value |
|---|---|---|---|---|
| OS at 42 months (ITT) | 70.2% | 46.0% | 0.71 (0.54–0.95) | P=0.00973 |
| Median OS | NE | 40.9 months | — | — |
| PFS2 at 42 months (exploratory) | 54.6% | 37.8% | 0.69 (0.55–0.87) | Not formally tested |
| Chemo-free at 42 months (exploratory) | 65.8% | 49.0% | 0.60 (0.46–0.77) | Not formally tested |
NSAI subgroup (n=495): 42-month OS 69.7% vs 43.0%; HR 0.70 (0.50–0.98) Tamoxifen subgroup (n=177): 42-month OS 71.2% vs 54.5%; HR 0.79 (0.45–1.38)
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| MONALEESA-7 | Ribociclib + ET + goserelin | Pre/perimenopausal HR+/HER2− ABC, 1L | PFS (reported previously) | 42-mo OS: 70.2% vs 46.0%; HR 0.71 | [1] |
| MONALEESA-2 | Ribociclib + letrozole | Postmenopausal HR+/HER2− ABC, 1L | PFS | See [5] | [5] |
| MONARCH 3 | Abemaciclib + NSAI | Postmenopausal HR+/HER2− ABC, 1L | PFS | See [7] | [7] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
NSAI + goserelin: HR 0.70 (95% CI 0.50–0.98) — statistically significant OS benefit Tamoxifen + goserelin: HR 0.79 (95% CI 0.45–1.38) — favors ribociclib but CI crosses unity Asian patients: HR 0.40 (95% CI 0.22–0.72) — marked benefit; mechanism unclear Non-Asian patients: HR 0.91 (95% CI 0.64–1.30) — attenuated effect Bone-only disease: HR 1.00 (95% CI 0.53–1.93) — no apparent benefit ≥3 metastatic sites: HR 0.58 (95% CI 0.37–0.91) — pronounced benefit with higher disease burden
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved: ribociclib + AI for pre/perimenopausal and postmenopausal HR+/HER2− advanced breast cancer (initial endocrine-based therapy) [2] |
| EMA | Approved: ribociclib + AI or fulvestrant for HR+/HER2− locally advanced or metastatic breast cancer |
⚠️ Verify current regulatory status before prescribing.
NCCN: Ribociclib + AI + ovarian suppression — preferred first-line for premenopausal HR+/HER2− metastatic breast cancer (Category 1) [3]
⚡ Grey Zones
- Optimal endocrine partner (NSAI vs tamoxifen) with ribociclib in premenopausal women remains unresolved — trial not powered for this comparison
- Bone-only metastatic disease showed no OS benefit (HR 1.00) — unclear if this subgroup truly does not benefit or if small sample size limits detection
- Striking Asian vs non-Asian treatment effect difference (HR 0.40 vs 0.91) is unexplained and hypothesis-generating only
- Optimal duration of CDK4/6 inhibitor therapy unknown — all patients treated until progression
- Detailed safety data (discontinuation rates, dose reductions, serious AEs) were in the Supplementary Appendix and are not available from this publication
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307-316. doi:10.1056/NEJMoa1903765
- Kisqali (ribociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7). Lancet Oncol. 2018;19(7):904-915.
- Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738-1748.
- Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive, advanced breast cancer. N Engl J Med. 2015;373:209-219.
- Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646.